These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 29392921)
21. Outcomes of multitarget therapy using mycophenolate mofetil and tacrolimus for refractory or relapsing lupus nephritis. Choi CB; Won S; Bae SC Lupus; 2018 May; 27(6):1007-1011. PubMed ID: 29448881 [TBL] [Abstract][Full Text] [Related]
22. Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up. Mok CC; Ying KY; Yim CW; Siu YP; Tong KH; To CH; Ng WL Ann Rheum Dis; 2016 Jan; 75(1):30-6. PubMed ID: 25550339 [TBL] [Abstract][Full Text] [Related]
23. T helper cell dysregulation with hepatitis B and rebalance with glucocorticoids. Lu ZH; Huang XP; Sun W; Zhu YL; Cui JJ; Chen W; Huang LH; Kuai SG; Du HJ; Ju ZX; Gan JH World J Gastroenterol; 2014 Dec; 20(48):18354-9. PubMed ID: 25561802 [TBL] [Abstract][Full Text] [Related]
24. Modulatory Effect of the Euro-Lupus Low-Dose Intravenous Cyclophosphamide Regimen on Circulating Immune Cells in Systemic Lupus Erythematosus. Gabcova G; Horak P; Mikulkova Z; Skacelova M; Zehnalova S; Smrzova A; Petrackova A; Mrazek F; Kriegova E Arch Immunol Ther Exp (Warsz); 2019 Dec; 67(6):415-425. PubMed ID: 31620814 [TBL] [Abstract][Full Text] [Related]
25. Comparative transcriptome analysis reveals a potential role for CaMK4 in γδT17 cells from systemic lupus erythematosus patients with lupus nephritis. Du B; Fan X; Lei F; Zhang S; Li G; Xi X Int Immunopharmacol; 2020 Mar; 80():106139. PubMed ID: 31978801 [TBL] [Abstract][Full Text] [Related]
26. New insights for regulatory T cell in lupus nephritis. Li Y; Tang D; Yin L; Dai Y Autoimmun Rev; 2022 Aug; 21(8):103134. PubMed ID: 35690245 [TBL] [Abstract][Full Text] [Related]
28. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Sfikakis PP; Boletis JN; Lionaki S; Vigklis V; Fragiadaki KG; Iniotaki A; Moutsopoulos HM Arthritis Rheum; 2005 Feb; 52(2):501-13. PubMed ID: 15693003 [TBL] [Abstract][Full Text] [Related]
29. IL-2 Therapy Diminishes Renal Inflammation and the Activity of Kidney-Infiltrating CD4+ T Cells in Murine Lupus Nephritis. Rose A; von Spee-Mayer C; Kloke L; Wu K; Kühl A; Enghard P; Burmester GR; Riemekasten G; Humrich JY Cells; 2019 Oct; 8(10):. PubMed ID: 31614462 [TBL] [Abstract][Full Text] [Related]
30. Role of Treg cells and TGF-β1 in patients with systemic lupus erythematosus: a possible relation with lupus nephritis. Xing Q; Su H; Cui J; Wang B Immunol Invest; 2012; 41(1):15-27. PubMed ID: 21563925 [TBL] [Abstract][Full Text] [Related]
31. Outcome and predictors of renal survival in patients with lupus nephritis: Comparison between cyclophosphamide and mycophenolate mofetil. Joo YB; Kang YM; Kim HA; Suh CH; Kim TJ; Park YW; Lee J; Lee JH; Yoo DH; Bae SC; Lee HS; Bang SY Int J Rheum Dis; 2018 May; 21(5):1031-1039. PubMed ID: 29611341 [TBL] [Abstract][Full Text] [Related]
32. Urine neutrophil gelatinase-associated lipocalin to predict renal response after induction therapy in active lupus nephritis. Satirapoj B; Kitiyakara C; Leelahavanichkul A; Avihingsanon Y; Supasyndh O BMC Nephrol; 2017 Aug; 18(1):263. PubMed ID: 28778196 [TBL] [Abstract][Full Text] [Related]
34. Th subset balance in lupus nephritis. Miyake K; Akahoshi M; Nakashima H J Biomed Biotechnol; 2011; 2011():980286. PubMed ID: 21904445 [TBL] [Abstract][Full Text] [Related]
35. Changes of memory B- and T-cell subsets in lupus nephritis patients. Kosalka J; Jakiela B; Musial J Folia Histochem Cytobiol; 2016; 54(1):32-41. PubMed ID: 27094637 [TBL] [Abstract][Full Text] [Related]
36. Ratio of T helper to regulatory T cells in synovial fluid and postoperative joint laxity after allograft anterior cruciate ligament reconstruction. Yang R; Zhang Z; Song B; Wang P; Wang L; Li W; Shen H Transplantation; 2012 Dec; 94(11):1160-6. PubMed ID: 23128997 [TBL] [Abstract][Full Text] [Related]
37. Lack of partial renal response by 12 weeks after induction therapy predicts poor renal response and systemic damage accrual in lupus nephritis class III or IV. Hanaoka H; Yamada H; Kiyokawa T; Iida H; Suzuki T; Yamasaki Y; Ooka S; Nagafuchi H; Okazaki T; Ichikawa D; Shirai S; Shibagaki Y; Koike J; Ozaki S Arthritis Res Ther; 2017 Jan; 19(1):4. PubMed ID: 28086993 [TBL] [Abstract][Full Text] [Related]
38. Treg17 cells are programmed by Stat3 to suppress Th17 responses in systemic lupus. Kluger MA; Melderis S; Nosko A; Goerke B; Luig M; Meyer MC; Turner JE; Meyer-Schwesinger C; Wegscheid C; Tiegs G; Stahl RA; Panzer U; Steinmetz OM Kidney Int; 2016 Jan; 89(1):158-66. PubMed ID: 26466322 [TBL] [Abstract][Full Text] [Related]
39. Th17 and Treg cells in adolescents with Graves' disease. Impact of treatment with methimazole on these cell subsets. Klatka M; Grywalska E; Partyka M; Charytanowicz M; Kiszczak-Bochynska E; Rolinski J Autoimmunity; 2014 May; 47(3):201-11. PubMed ID: 24443787 [TBL] [Abstract][Full Text] [Related]
40. CNI induced Th17/Treg imbalance and susceptibility to renal dysfunction in renal transplantation. Li Y; Shi Y; Huang Z; Bai Y; Niu Q; Cai B; Wang L; Feng W Int Immunopharmacol; 2011 Dec; 11(12):2033-8. PubMed ID: 21911083 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]